| Literature DB >> 30087575 |
Matthew J Kaptein1,2, John S Kaptein2, Zayar Oo2, Elaine M Kaptein2.
Abstract
BACKGROUND: Ultrasound (US) assessment of intravascular volume may improve volume management of dialysis patients. We investigated the relationship of intravascular volume evaluated by inferior vena cava (IVC) US to net volume changes with intermittent hemodialysis (HD) in critically ill patients.Entities:
Keywords: acute kidney injury; chronic kidney disease; critical illness; end-stage renal disease; inferior vena cava ultrasound; intermittent hemodialysis/ultrafiltration; intradialytic hypotension; intravascular volume
Year: 2018 PMID: 30087575 PMCID: PMC6061398 DOI: 10.2147/IJNRD.S165744
Source DB: PubMed Journal: Int J Nephrol Renovasc Dis ISSN: 1178-7058
Individual hemodialysis patient and encounter characteristics
| (A) Individual patient data
| |||||
|---|---|---|---|---|---|
| Demographics | All patients n=113 | ESRD | AKI n=47 | AKI/CKD | |
| Age (years) (median, range) | 58, 23–87 | 58, 27–81 | 55, 23–79 | 62, 27–87 | 0.075 |
| Gender (M/F) | 80/33 | 32/15 | 32/15 | 16/3 | 0.33 |
| Primary disease states | |||||
| Sepsis/shock | 41.6% | 27.7% | 46.8% | 63.2% | 0.018 |
| Cardiac disease | 30.1% | 34.0% | 23.4% | 36.8% | 0.41 |
| Acute liver failure | 18.6% | 6.4% | 31.9% | 15.8% | 0.005 |
| Respiratory failure | 22.1% | 12.8% | 34.0% | 15.8% | 0.036 |
| Trauma/Surgical | 9.7% | 12.8% | 8.5% | 5.3% | 0.59 |
| Metabolic | 15.9% | 27.7% | 10.6% | 0% | 0.003 |
| Bleeding/hematologic | 19.5% | 23.4% | 14.9% | 21.1% | 0.56 |
| Other | 23.0% | 12.8% | 27.7% | 36.8% | 0.062 |
| Comorbidities | |||||
| Diabetes mellitus | 41.6% | 61.7% | 19.1% | 47.4% | <0.001 |
| Hypertension | 42.5% | 66.0% | 17.0% | 47.4% | <0.001 |
| Malignancy | 12.4% | 4.3% | 21.3% | 10.5% | 0.35 |
| Postoperative | 14.2% | 8.5% | 19.1% | 15.8% | 0.31 |
| Cirrhosis | 21.2% | 10.6% | 31.9% | 21.1% | 0.037 |
| Chronic cardiovascular disease | 41.6% | 40.4% | 34.0% | 63.2% | 0.094 |
| Chronic hematologic/bleeding | 22.1% | 21.3% | 25.5% | 15.8% | 0.67 |
| Other | 19.5% | 12.8% | 25.5% | 21.1% | 0.32 |
| Echocardiography | 86 | 35 | 35 | 16 | |
| Days from echo to IVC US (median, range from before to after IVC) | 2, 47–37 | 0.5, 17–37 | 2, 47–9 | 4, 45–10 | |
| EF<35% (% of group) | 22.1% | 17.1% | 22.9% | 31.3% | 0.46 |
| EF 35–50% (% of group) | 18.6% | 20.0% | 17.1% | 18.8% | 0.93 |
| EF >50% (% of group) | 59.3% | 62.9% | 60.0% | 50.0% | 0.60 |
| Initial SOFA score (median, range) | 10, 4–20 | 7, 4–20 | 13, 4–20 | 10, 5–18 | <0.001 |
| ICU survival (%) | 75% | 81% | 70% | 74% | 0.48 |
| Hospital survival (%) | 71% | 77% | 68% | 63% | 0.48 |
| Laboratory values with first encounter | |||||
| White blood count (103/µL) (median, range) (normal range: 4.5–10.0) | 10.7, 0.5–42.5 | 9.4, 3.4–23.3 | 11.9, 0.5–42.5 | 13.4, 3.3–21.6 | 0.30 |
| Hemoglobin (g/dL) (median, range) (normal range: 13.5–16.5) | 9.1, 2.8–17.0 | 9.5, 2.8–13.9 | 9.1, 4.3–17.0 | 8.9, 7.0–10.4 | 0.48 |
| Serum albumin (g/dL) (median, range) (normal range: 3.5–5.0) | 2.9, 1.2–4.6 | 3.2, 1.7–4.6 | 2.7, 1.2–4.6 | 2.7, 1.6–3.6 | 0.005 |
|
| |||||
|
| |||||
|
| |||||
| SOFA parameters | |||||
| SOFA scores (median, range) | 10, 4–20 | 8, 4–20 | 11, 4–20 | 10, 5–18 | <0.001 |
| Mechanical ventilation (% of encounters) | 59.4% | 53.7% | 63.8% | 55.3% | 0.32 |
| PaO2 (mmHg) | 100, 35–339 | 100, 35–339 | 100, 44–256 | 100, 45–191 | 0.89 |
| FIO2 (%) | 40, 21–100 | 35, 21–100 | 40, 21–100 | 40, 21–70 | 0.002 |
| Platelet count (×103/µL) (median, range) (normal range:160–360) | 125, 11–865 | 151, 24–468 | 106, 11–865 | 156, 11–607 | 0.076 |
| Glasgow coma score (1–15) | 0.11 | ||||
| Mild (13–15) (% of encounters) | 45.5% | 50.7% | 43.1% | 44.7% | |
| Moderate (9–12) (% of encounters) | 28.3% | 34.3% | 27.7% | 21.3% | |
| Severe (≤8) (% of encounters) | 26.2% | 14.9% | 29.2% | 34.0% | |
| Bilirubin (mg/dL) (median, range) (normal range: 0.3–1.4) | 1.0, 0.1–36.9 | 0.5, 0.2–8.8 | 1.3, 0.1–33.8 | 1.2, 0.2–36.9 | <0.001 |
| Pre-HD systolic BP (mmHg) (median, range) | 120, 58–206 | 126, 82–185 | 119, 58–206 | 111, 73–161 | 0.040 |
| Pre-HD diastolic BP (mmHg) (median, range) | 59, 26–117 | 58, 29–101 | 63, 26–117 | 54, 34–101 | <0.001 |
| Pre-HD MAP (mmHg) (median, range) | 79, 47–139 | 82, 53–114 | 81, 49–139 | 75, 47–111 | 0.036 |
| Levels of hypotension (cardiac component of SOFA) | 0.22 | ||||
| (SOFA 0) No hypotension | 60.7% | 67.2% | 60.0% | 53.2% | |
| (SOFA+1) Pre-HD MAP <70 mmHg | 9.8% | 10.4% | 9.2% | 10.6% | |
| Intravenous vasopressor use | |||||
| (SOFA+2) Dopamine ≤5 µg/kg/min or dobutamine any dose | 0.4% | 0% | 0% | 2.1% | |
| (SOFA+3) Dopamine >5 µg/kg/min or Epi/Norepi ≤0.1 µg/kg/min | 12.3% | 4.5% | 13.8% | 19.1% | |
| (SOFA+4) Dopamine > 15 µg/kg/min or Epi/Norepi >0.1 µg/kg/min | 16.8% | 17.9% | 16.9% | 14.9% | |
| Category of IDH (% of encounters) | 0.27 | ||||
| 0 No criteria for IDH | 5.3% | 3.0% | 5.4% | 8.5% | |
| 1 Received normal saline >500 mL (250 mL prime and 250 mL rinse-back required for each HD procedure) or albumin IV | 31.1% | 38.8% | 28.5% | 27.7% | |
| 2a MAP <65 mmHg during HD, no vasopressors given, and HD not discontinued due to hypotension | 9.4% | 6.0% | 8.5% | 17.0% | |
| 2b Pre-HD hypotension requiring a constant dose of vasopressors to maintain BP before and during HD/UF | 10.2% | 7.5% | 10.0% | 14.9% | |
| 3 SBP decreased >50 mmHg or MAP decreased >20% | 30.3% | 31.3% | 34.6% | 17.0% | |
| 4 Vasopressor therapy initiated or dose increased, or dialysis stopped ≤2 h due to intractable intradialytic hypotension | 13.5% | 13.4% | 13.1% | 14.9% | |
| Interval between IVC US and HD (h) (median, range) | 8.0, 0–24 | 7.6, 0–24 | 8.0, 0–24 | 8.0, 0–24 | 0.74 |
| Duration of HD/UF (h) (median, range) | 3.5, 0.17–4.8 | 3.5, 2.0–4.5 | 3.5, 0.17–4.8 | 3.5, 1.5–4.1 | 0.37 |
| Weight at time of encounter (kg) (median, range) | 78, 43–211 | 71, 43–119 | 81, 50–175 | 82, 55–211 | <0.001 |
| Rate of net volume change (mL/kg/h) (median, range) | −6.0, −18.3 to +14.4 | −7.0, −16.5 to +4.8 | −6.0, −15.3 to +14.4 | −5.3, −18.5 to +5.7 | 0.067 |
| UF >13 mL/kg/h (% of encounters) | 6.6% | 11.9% | 4.6% | 4.3% | |
Notes:
ESRD group included patients previously receiving HD or initiated on HD with prior CKD5.
Baseline renal function frequently unknown.
P-value indicates comparison among ESRD, AKI, and AKI/CKD groups.
Primary disease states and comorbidities at the time of the nephrology consult; many patients had more than one major illness.
Other primary disorders included: Volume overload (8.0%), burns (4.4%), autoimmune disorders (3.5%), acute pancreatitis (2.7%), pulmonary embolism (2.7%), and pulmonary hypertension (1.8%).
Other comorbidities included: Infection (6.2%), respiratory failure (5.3%), autoimmune disorders (4.4%), substance/polysubstance abuse (2.7%), and pulmonary hypertension (0.9%).
Echocardiography data from studies performed within 2 months of the patient encounter.
ESRD is different from AKI.
ESRD is different from AKI/CKD,
AKI is different from AKI/CKD.
In patients who did not have an arterial blood gas available, PaO2 was estimated from digital pulse oxygen saturation (SPO2),26 and in those not mechanically ventilated, FIO2 was estimated from oxygen delivery by nasal cannula.27
P-value examines distribution of Glasgow coma score mild, moderate, severe among ESRD, AKI, AKI/CKD groups (columns). Percentages indicate % encounters with a given SOFA component score within each group (column).
P-value examines distribution of cardiac SOFA scores among ESRD, AKI, AKI/CKD groups (columns). Percentages indicate % encounters with a given SOFA component score within each group (column).
P-value examines distribution of IDH categories among ESRD, AKI, AKI/CKD groups (columns). Percentages indicate % encounters with a given SOFA component score within each group (column).
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; CVP, central venous pressure; EF, ejection fraction; ESRD, end-stage renal disease, HD, hemodialysis; ICU, intensive care unit; IDH, intradialytic hypotension; IVC, inferior vena cava; PAOP, mean pulmonary artery occlusion pressure; SOFA, Sequential Organ Failure Assessment; UF, ultrafiltration.
Figure 1(A) The proportion of patients who achieved a given net UF volume is strongly correlated with IVC CI, when n-weighted proportions are plotted against the midpoint of each IVC CI interval. IVCmax ≤0.7cm was considered “totally collapsed” and IVC CI was plotted as 100%. (B) The probability of whether a given net UF volume was achieved based on IVC CI as determined using logistic regression analysis. The vertical lines represent IVC CI cutoff values at 20% and 50%.
Abbreviations: CI, collapsibility index; IVC, inferior vena cava; UF, ultrafiltration.
Sensitivity/specificity and logistic regression analyses
| Group | Predictor | UF (L) | Cutoff | SN/SP (%) | AUC | ||
|---|---|---|---|---|---|---|---|
| Entire cohort (n=244) | IVC CI (%) | ≥0.5 | <23.0 | 70 | 0.72±0.04 | <0.001 | <0.001 |
| ≥1.0 | <20.9 | 65 | 0.71±0.04 | <0.001 | <0.001 | ||
| ≥1.5 | <19.6 | 63 | 0.68±0.04 | <0.001 | <0.001 | ||
| ≥2.0 | <18.5 | 58 | 0.62±0.04 | <0.001 | 0.003 | ||
| Entire cohort (n=244) | IVCmax (cm) | ≥0.5 | >1.97 | 60 | 0.66±0.04 | <0.001 | <0.001 |
| ≥1.0 | >2.02 | 57 | 0.64±0.04 | <0.001 | <0.001 | ||
| ≥1.5 | >2.03 | 59 | 0.64±0.04 | <0.001 | <0.001 | ||
| ≥2.0 | >2.05 | 59 | 0.64±0.04 | <0.001 | <0.001 | ||
| Entire cohort (n=244) | IVCmin (cm) | ≥0.5 | >1.49 | 66 | 0.72±0.04 | <0.001 | <0.001 |
| ≥1.0 | >1.55 | 63 | 0.70±0.04 | <0.001 | <0.001 | ||
| ≥1.5 | >1.62 | 63 | 0.67±0.04 | <0.001 | <0.001 | ||
| ≥2.0 | >1.65 | 60 | 0.64±0.04 | <0.001 | <0.001 | ||
| Entire cohort (n=116) | Mean CVP (cm H2O) | ≥0.5 | >9.58 | 55 | 0.55±0.06 | 0.212 | 0.936 |
| ≥1.0 | >9.74 | 54 | 0.53±0.06 | 0.300 | 0.745 | ||
| ≥1.5 | >9.68 | 57 | 0.56±0.06 | 0.155 | 0.908 | ||
| ≥2.0 | >9.94 | 53 | 0.48±0.05 | 0.380 | 0.298 | ||
| Entire cohort (n=21) | Mean PAOP (mmHg) | ≥0.5 | >19.5 | 50 | 0.59±0.14 | 0.272 | 0.450 |
| ≥1.0 | >19.5 | 50 | 0.59±0.14 | 0.272 | 0.450 | ||
| ≥1.5 | >20.4 | 39 | 0.45±0.14 | 0.370 | 0.811 | ||
| ≥2.0 | >19.9 | 36 | 0.37±0.13 | 0.147 | 0.240 | ||
| Entire cohort (n=23) | Cardiac output (L/min) | ≥0.5 | <5.24 | 56 | 0.58±0.12 | 0.266 | 0.975 |
| ≥1.0 | <5.24 | 56 | 0.58±0.12 | 0.266 | 0.975 | ||
| ≥1.5 | <5.16 | 50 | 0.38±0.13 | 0.187 | 0.278 | ||
| ≥2.0 | <5.17 | 62 | 0.62±0.13 | 0.348 | 0.843 | ||
| Ventilated (n=145) | IVC CI (%) | ≥0.5 | <22.0 | 71 | 0.70±0.07 | 0.002 | <0.001 |
| ≥1.0 | <20.3 | 65 | 0.70±0.06 | <0.001 | <0.001 | ||
| ≥1.5 | <16.9 | 59 | 0.68±0.05 | <0.001 | <0.001 | ||
| ≥2.0 | <16.5 | 56 | 0.59±0.05 | 0.030 | 0.033 | ||
| Non-ventilated (n=99) | IVC CI (%) | ≥0.5 | <24.0 | 69 | 0.72±0.06 | <0.001 | 0.009 |
| ≥1.0 | <22.1 | 65 | 0.71±0.05 | <0.001 | 0.004 | ||
| ≥1.5 | <20.3 | 59 | 0.67±0.05 | <0.001 | 0.015 | ||
| ≥2.0 | <20.3 | 57 | 0.64±0.06 | 0.008 | 0.058 | ||
| Vasopressors (n=73) | IVC CI (%) | ≥0.5 | <20.5 | 69 | 0.73±0.07 | 0.001 | 0.025 |
| ≥1.0 | <18.4 | 66 | 0.71±0.07 | 0.001 | 0.022 | ||
| ≥1.5 | <17.2 | 72 | 0.78±0.06 | <0.001 | <0.001 | ||
| ≥2.0 | <13.7 | 65 | 0.66±0.07 | 0.008 | 0.024 | ||
| No vasopressors (n=171) | IVC CI (%) | ≥0.5 | <23.9 | 69 | 0.72±0.05 | <0.001 | <0.001 |
| ≥1.0 | <21.8 | 65 | 0.70±0.05 | <0.001 | <0.001 | ||
| ≥1.5 | <20.1 | 59 | 0.64±0.04 | <0.001 | 0.001 | ||
| ≥2.0 | <19.8 | 58 | 0.60±0.04 | 0.013 | 0.018 | ||
| ESRD (n=67) | IVC CI (%) | ≥0.5 | <20.7 | 65 | 0.77±0.08 | <0.001 | 0.008 |
| ≥1.0 | <18.4 | 54 | 0.62±0.08 | 0.062 | 0.099 | ||
| ≥1.5 | <18.1 | 55 | 0.59±0.07 | 0.099 | 0.285 | ||
| ≥2.0 | <17.3 | 56 | 0.57±0.07 | 0.166 | 0.496 | ||
| AKI (n=130) | IVC CI (%) | ≥0.5 | <22.2 | 65 | 0.64±0.07 | 0.017 | 0.111 |
| ≥1.0 | <22.1 | 68 | 0.69±0.06 | <0.001 | 0.007 | ||
| ≥1.5 | <20.2 | 61 | 0.66±0.05 | <0.001 | 0.008 | ||
| ≥2.0 | <19.6 | 58 | 0.58±0.05 | 0.054 | 0.115 | ||
| AKI/CKD (n=47) | IVC CI (%) | ≥0.5 | <23.8 | 86 | 0.87±0.06 | <0.001 | 0.001 |
| ≥1.0 | <21.9 | 82 | 0.85±0.06 | <0.001 | 0.001 | ||
| ≥1.5 | <20.1 | 76 | 0.85±0.06 | <0.001 | 0.002 | ||
| ≥2.0 | <17.7 | 67 | 0.74±0.08 | 0.001 | <0.001 | ||
| Patients with more than one encounter: first encounter (n=43) | IVC CI (%) | ≥0.5 | <26.2 | 74 | 0.79±0.07 | <0.001 | 0.041 |
| ≥1.0 | <25.2 | 75 | 0.74±0.08 | 0.002 | 0.084 | ||
| ≥1.5 | <22.4 | 75 | 0.75±0.08 | <0.001 | 0.033 | ||
| ≥2.0 | <20.9 | 60 | 0.60±0.09 | 0.125 | 0.267 | ||
| Patients with more than one encounter: second encounter (n=43) | IVC CI (%) | ≥0.5 | <28.8 | 76 | 0.82±0.10 | <0.001 | 0.010 |
| ≥1.0 | <23.7 | 65 | 0.70±0.10 | 0.020 | 0.042 | ||
| ≥1.5 | <20.4 | 63 | 0.68±0.08 | 0.012 | 0.107 | ||
| ≥2.0 | <20.3 | 56 | 0.59±0.09 | 0.152 | 0.320 |
Notes: The cutoff was chosen at the point where sensitivity equals specificity.
P-value <0.05 indicates that the area under the ROC is significantly >0.5 and that there is a relationship between the variable and whether a specific UF volume was removed or not.
P-value <0.05 indicates that the variable is a significant predictor by logistic regression of whether a specific UF volume was removed or not.
Abbreviations: AKI, acute kidney injury; AUC, area under the ROC curve; CI, collapsibility index; CKD, chronic kidney disease; CVP, central venous pressure; ESRD, end-stage renal disease; IVC, inferior vena cava; n, number of encounters; PAOP, mean pulmonary artery occlusion pressure; ROC, receiver operating characteristic; SN, sensitivity; SP, specificity; UF, ultrafiltration.
χ2 analyses comparing pre-ultrasound clinical intravascular volume assessments to IVC collapsibility index groups for initial and subsequent encounters
| IVC CI subgroups | Initial encounters: | Subsequent encounters: | ||||
|---|---|---|---|---|---|---|
| Hypervolemia | Euvolemia | Hypovolemia | Hypervolemia | Euvolemia | Hypovolemia | |
| CI <20% | 33 | 15 | 7 | 42 | 30 | 5 |
| 20% ≤ CI ≤50% | 21 | 12 | 7 | 18 | 18 | 4 |
| CI >50% | 6 | 5 | 7 | 0 | 8 | 6 |
|
| ||||||
|
| ||||||
| $ | Hypervolemia | Not-hypervolemia | Hypervolemia | Not-hypervolemia | ||
| CI <20% | 33 | 22 | SN 60% | 42 | 35 | SN 55% |
| CI ≥20% | 27 | 31 | SP 53% | 18 | 36 | SP 67% |
|
| ||||||
|
| ||||||
| @ | Hypovolemia | Not-hypovolemia | Hypovolemia | Not-hypovolemia | ||
| CI >50% | 7 | 11 | SN 39% | 6 | 8 | SN 43% |
| CI ≤50% | 14 | 81 | SP 85% | 9 | 108 | SP 92% |
Notes:
P-value indicates the probability of whether the distributions are random.
Hypervolemia, euvolemia and hypovolemia are clinical assessments. The category not-hypovolemia groups patients in the categories of euvolemia and hypervolemia.
Frequency of occurrence is higher than would be expected due to chance.
Frequency of occurrence is lower than would be expected due to chance.
Proportion of outcomes for which there is agreement ± 95% confidence interval. Concordance is defined as percentage of encounters in which clinical assessment of hypervolemia agrees with IVC CI <20%, euvolemia agrees with IVC CI ≥20% to ≤50%, and hypovolemia agrees with IVC CI >50%. $ Test is whether clinical assessment of hypervolemia is a predictor of CI <20%; SN and SP for this are indicated. @ Test is whether clinical assessment of hypovolemia is a predictor of CI >50%; SN and SP for this are indicated.
Abbreviations: CI, collapsibility index; IVC, inferior vena cava; SN, sensitivity; SP, specificity.
Figure 2(A) Relationship of net volume change achieved to net volume change recommended in ESRD, AKI, and AKI with CKD encounters. (B) Relationship of net volume change achieved to net volume change recommended for encounters with different categories of IDH.
Notes: The net volume change achieved is progressively less than recommended as IDH severity increases, with the exception of category 2a. Definitions of IDH categories: IDH 0: No criteria for IDH; IDH 1: Received normal saline >500 mL or albumin IV to treat hypotension; IDH 2a: MAP <65 mmHg during HD, no vasopressors given, and HD not discontinued due to hypotension; IDH 2b: Pre-HD hypotension requiring a constant dose of vasopressors to maintain BP before and during HD/UF; IDH 3: SBP decreased >50 mmHg or MAP decreased >20%; IDH 4: Vasopressor therapy initiated or dose increased, or dialysis stopped ≤2 h due to intractable hypotension. For net volume recommended, data points are plotted at the mid-point of the recommended range with slight offsets; regression lines are not offset. Negative values denote net volume removed.
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; ESRD, end-stage renal disease; HD, hemodialysis; IDH, intradialytic hypotension; MAP, mean arterial pressure; SBP, systolic blood pressure; UF, ultrafiltration.
Figure 3The relationship of rate of net volume change achieved is plotted for all encounters by categories of severity of intradialytic hypotension.
Notes: Negative values denote net volume removed. Boxes indicate medians, 5th and 95th percentile values. There is no relationship between the rate of net volume change and the category of IDH. Definitions of IDH categories are as in Figure 2B.
Abbreviation: IDH, intradialytic hypotension.